Entities / Company
Organon & Co..
pharmaceutical company
- Reports this week
- 1
- Active events
- 1
- Connections
- 57
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
Earlier this month
One to three months ago
Gone quiet
No new reports in 90+ days-
Organon & Co. gained exclusive commercialization rights for the drug Pyzchiva.Some support1 report
-
Organon & Co. is headquartered in Jersey City, New Jersey, and uses LinkedIn for communication.Some support1 report
-
Recursion Pharmaceuticals and Organon & Co. both reported positive Earnings ESP on July 22, 2025.Some support1 report
-
Trump pledged to unleash American oil and gas production involving Organon & Co.Some support2 reports
-
Several healthcare companies, including Kadant and Hims & Hers Health, reported significant market-beating returns over five years.Speculative1 report
-
Analyst inquiries to Organon & Co. management covered competition risk, share repurchases, and sales targets.Speculative1 report
-
The American Academy of Dermatology recommended Organon & Co.'s cream for the management of Atopic Dermatitis.Some support2 reports
-
Juan Camilo Arjona Ferreira was appointed CMO at Organon & Co. in July 2025.Some support2 reports
-
Both Medpace and Organon & Co. are being considered for investment in the Medical Services sector.Some support2 reports
-
Organon acquired U.S. rights to TOFIDENCE from Biogen and laid off employees at its Jersey City headquarters.Some support1 report
-
Zacks.com tracked Organon & Co.'s stock performance on July 23, 2025.Some support2 reports
-
Kevin Ali was appointed as the CEO of Organon & Co. on August 7, 2025.Some support1 report
-
Investors consider AI stocks for greater upside potential, involving Organon & Co.Some support1 report
-
Organon shares returned -8.2% on August 12, 2025, while the Zacks Medical Services industry lost 2.5%.Some support2 reports
-
Planned Parenthood issues are causing market hesitancy, with Matthew Walsh providing a financial outlook.Some support1 report
-
Nexplanon and Organon & Co. are facing market headwinds in Europe, including the loss of exclusivity for Atozet and questioning the impact of potential EU tariffs on 2026 margins.Some support1 report
-
Robert Bruce made various stock transactions in LyondellBasell, Vicor Corp, The Chemours Co, and Organon & Co. on August 15, 2025.Some support1 report
-
A podcast discussed thermal management systems for energy reduction, innovations in materials like cement and steel, and transforming buildings and transport.Some support2 reports
-
FDA recognized Hadlima as an interchangeable biosimilar for Humira, supporting Organon's biosimilars pipeline.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Organon & Co. this week
News at the entities that move Organon & Co. most-
MarketBeat Mentioned togetherMarketBeat reports analyst recommendations for finance companies First Bancorp and Bankwell Financial Group.Moves Organon & Co.
-
Trane Technologies OperationalCEO David Regnery sold a large block of company stock and TD Waterhouse reduced its position in Trane Technologies.Moves Organon & Co.
-
SEC StructuralCelularity, Inc. filed with the SEC regarding its stock ownership on October 21, 2026.Moves Organon & Co.
-
Korea Shared contextDave Rosa, CEO of the company using ION, reports accelerating adoption of procedures across Korea, Europe, and China.Moves Organon & Co.
-
China Shared contextEU members reported sustained emissions reduction while wars in Iran disrupted global oil and gas supply.Moves Organon & Co.
-
Europe Shared contextWestern societies are currently grappling with a growing crisis of hope.Moves Organon & Co.
Connections
The 9 strongest of 57, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Sun Pharmaceutical Transactional
Sun Pharmaceutical has proposed an $11.75 billion acquisition bid for Organon & Co.
-
Juan Camilo Arjona Ferreira Structural
Juan Camilo Arjona Ferreira holds the role of CMO and Head of R&D at Organon & Co.
-
SEC Structural
Organon & Co. must comply with SEC regulations by filing information regarding institutional holdings.
-
Natera Operational
Both medical companies are noted to be competing for investment capital.
-
Trane Technologies Operational
Both companies are active in the thermal management systems market, with evidence suggesting a supply relationship.
-
MarketBeat Mentioned together
MarketBeat provides analyst recommendations and coverage for Organon & Co.
-
Korea Shared context
Organon & Co. operates in markets that include Korea.
-
Europe Shared context
Organon & Co. operates within the European market, particularly concerning biosimilars and exclusivity.
Show all 9 connections
-
China Shared context
Organon & Co. operates within the markets of China.
History
Events by the month they beganOctober 2026
1 eventSeptember 2026
2 eventsAugust 2026
1 eventShow 1 earlier month
June 2026
19 events- Organon & Co. gained exclusive commercialization rights for the drug Pyzchiva.
- Organon & Co. is headquartered in Jersey City, New Jersey, and uses LinkedIn for communication.
- Recursion Pharmaceuticals and Organon & Co. both reported positive Earnings ESP on July 22, 2025.
- Trump pledged to unleash American oil and gas production involving Organon & Co.
- Several healthcare companies, including Kadant and Hims & Hers Health, reported significant market-beating returns over five years.
- Analyst inquiries to Organon & Co. management covered competition risk, share repurchases, and sales targets.
- The American Academy of Dermatology recommended Organon & Co.'s cream for the management of Atopic Dermatitis.
- Juan Camilo Arjona Ferreira was appointed CMO at Organon & Co. in July 2025.
- Both Medpace and Organon & Co. are being considered for investment in the Medical Services sector.
- Organon acquired U.S. rights to TOFIDENCE from Biogen and laid off employees at its Jersey City headquarters.
- Zacks.com tracked Organon & Co.'s stock performance on July 23, 2025.
- Kevin Ali was appointed as the CEO of Organon & Co. on August 7, 2025.
- Investors consider AI stocks for greater upside potential, involving Organon & Co.
- Organon shares returned -8.2% on August 12, 2025, while the Zacks Medical Services industry lost 2.5%.
- Planned Parenthood issues are causing market hesitancy, with Matthew Walsh providing a financial outlook.
- Nexplanon and Organon & Co. are facing market headwinds in Europe, including the loss of exclusivity for Atozet and questioning the impact of potential EU tariffs on 2026 margins.
- Robert Bruce made various stock transactions in LyondellBasell, Vicor Corp, The Chemours Co, and Organon & Co. on August 15, 2025.
- A podcast discussed thermal management systems for energy reduction, innovations in materials like cement and steel, and transforming buildings and transport.
- FDA recognized Hadlima as an interchangeable biosimilar for Humira, supporting Organon's biosimilars pipeline.